Unicycive Therapeutics, Inc. (UNCY) OLC NDA Resubmission Accepted; PDUFA Set for Mar 25, 2027

Unicycive Therapeutics (UNCY) announced the FDA accepted its resubmitted NDA for oxylanthanum carbonate, setting a PDUFA action date of March 25, 2027. The resubmission includes CMC data from a new manufacturer, addressing prior CRLs related to manufacturing issues.

Original reporting
Published Oct 21, 2026, 11:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 11:15 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Unicycive Therapeutics, Inc. (UNCY) OLC NDA Resubmission Accepted; PDUFA Set for Mar 25, 2027 — source image
Decision brief

The 30-second read

$UNCYBullishMed
01

Why it matters

Regulatory acceptance is a key milestone that can materially affect valuation.

02

Market read

The news is primarily relevant to biotech investors and may influence peer stocks.

03

What to watch

Potential competition from other phosphate binders and the long PDUFA timeline may temper price gains.

Relevance 8/10Novelty 8/10Timing: today

Background

Unicycive Therapeutics is a clinical‑stage biotech developing oxylanthanum carbonate for hyperphosphatemia.

Company-level read

Ticker impact

$UNCYBullishHigh confidence
Context

FDA accepted Unicycive's resubmitted NDA for oxylanthanum carbonate with a PDUFA target date of Mar 25, 2027, resetting the approval timeline.

Expected impact

upward pressure as market prices in the renewed approval path.

Evidence & confidence

The acceptance removes prior CRL issues and sets a clear review timeline, a material catalyst for a biotech.

Market effects

Strengthens outlook for the renal‑failure drug segment and may boost peer biotech valuations.

U.S. biotech market sees modest positive sentiment.

Limited to investors tracking FDA pipelines; no broad market effect.

Counterpoint

If the FDA later issues additional data requests, the initial optimism could reverse.

Key entities

  • Unicycive Therapeutics, Inc.

    Biotech firm pursuing FDA approval for oxylanthanum carbonate.

  • FDA

    U.S. Food and Drug Administration overseeing the NDA review.

Related articles

MedAI 8/10

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission and PDUFA

Unicycive Therapeutics announced the FDA accepted its resubmitted NDA for Oxylanthanum Carbonate (OLC), setting a PDUFA target action date of March 25, 2027. The resubmission addresses manufacturing deficiencies cited in a prior CRL. OLC is an investigational phosphate binder for CKD patients on dialysis, with potential market advantages due to its formulation.

$UNCYMed

FDA accepts Unicycive resubmission for kidney drug application

Unicycive Therapeutics (UNCY) announced the FDA accepted its resubmitted New Drug Application for oxylanthanum carbonate, a treatment for hyperphosphatemia in chronic kidney disease patients. The FDA set a target action date of March 25, 2027. The resubmission includes new manufacturing data from a different vendor, following a Complete Response Letter in June 2026. The company hopes for potential approval and does not know if the FDA will conduct a pre-approval inspection.

$UNCYMedAI 8/10

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027

Unicycive Therapeutics (Nasdaq: UNCY) announced FDA acceptance of its resubmitted NDA for oxylanthanum carbonate, a treatment for hyperphosphatemia in chronic kidney disease patients. The FDA set a PDUFA date of March 25, 2027. The resubmission includes new manufacturing data. The company hopes for potential approval, pending FDA review and possible inspections.

$UNCYHighAI 8/10

Why is Unicycive Therapeutics stock rallying today?

Unicycive Therapeutics (UNCY) stock rose 3.5% after the FDA accepted its resubmission for oxylanthanum carbonate, a treatment for chronic kidney disease. The FDA set a March 2027 target action date. The resubmission includes new manufacturing data addressing prior deficiencies. The broader market also gained, supporting small-cap biotech stocks. The company faces ongoing legal action, capping gains.